SecBot SecBot

RDY

DR REDDYS LABORATORIES LTD
NYSE· Pharmaceutical Preparations· Inc. K7· CIK 0001135951 Biotech & Drug Discovery
$14.70 −0.04 (−0.27%)
Nov 16 4:00 PM ET · prev $14.74
Market cap
$12.3B
Large cap
Consensus
Buy
62% Buy or better · 42 analysts
Median target
🔒 Subscribers only
1 year
+5.3%
from $13.96 · Nov 17
30 days
+12.4%
from $13.08
52-week range
$11.38–15.38
−4% from high · low Jul 22
Avg volume 20D
2.93M
shares / day
Short interest
25.30M
≈3.0% of shares · −3.2%
Days to cover
7.8
at average volume
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
73
analyzed by SecBot
SecBot read MIXED 26 reports · 90 days
Balance 3 bearish · 2 bullish · 21 neutral oldest → newest, height = score
Avg score ·High conf. 21/26

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 21 added (1 new), 29 trimmed or exited.

  • AnalystsBULLISH

    26 of 42 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −3.2% to 25.30M shares. 7.8 days to cover, ≈3.0% of shares.

  • TrendUPTREND

    12% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 26.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYDOUBLED24,293,913$306.6M
Robeco Institutional Asset Management B.V.TRIM8,680,810$109.6M
FRANKLIN TEMPLETON INCDOUBLED6,396,364$94.5M
UBS Group AGTRIM1,144,212$14.4M
Grantham, Mayo, Van Otterloo & Co. LLCDOUBLED606,808$7.7M
CITIGROUP INCDOUBLED504,797$6.4M
Jump Financial, LLCDOUBLED389,000$4.9M
MARSHALL WACE, LLPNEAR_EXIT268,102$3.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

42 analysts
Buy 62% rate it Buy or better
Strong Buy11Buy15Hold9Sell7Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 29, 2026Citigroup
UPGRADE
UPGRADEBuy

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
25,297,771
shares short
-3.2%
vs prior settlement
7.8
days to cover
≈3.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 SEC
Dr. Reddy's filed a Form 6-K to announce that management will participate in investor conferences in Mumbai (JM…
6-K · Impact 2/10
Nov 9, 2026 SEC
Institutional activity in RDY was mixed during Q3 2026, with 6 small buyers (net +$6.4M) and 6 sellers (net -$153.5M)…
INST-CLUSTER · Impact 3/10
Sep 30, 2026 Inst.
MORGAN STANLEY · DOUBLED
24,293,913 shares ($306.6M)
Sep 30, 2026 Inst.
Robeco Institutional Asset Management · TRIM
8,680,810 shares ($109.6M)
Sep 24, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Jun 1, 2026 Event
Valganciclovir
WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENES

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

73 filings · 7 bullish · 7 bearish · 1 mixed · 58 neutral
All RDY filing & press-release reports (73)